Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082209 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
NCT03082209 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 153 participants.
The verdict
NCT03082209, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
Study Summary
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.
Interventions
- DRUG Venetoclax
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG ABBV-621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2022-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03082209
The ClinicalTrials.gov registry entry for NCT03082209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT03082209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03082209 about?
NCT03082209 is a clinical study titled "A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies". This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignanc...
What is the current status of trial NCT03082209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2017-03-20. Estimated completion is 2022-01-21.
What interventions are being tested in trial NCT03082209?
The interventions under investigation include: Venetoclax (DRUG), Bevacizumab (DRUG), FOLFIRI (DRUG), ABBV-621 (DRUG).
Who is sponsoring clinical trial NCT03082209?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.